scFv-based "grababody" as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumors

Cancer Research

Volumn 73, Issue 8, 2013, Pages 2619-2627

  Cai, Zheng ^a   Fu, Ting ^a   Nagai, Yasuhiro ^a   Lam, Lian ^a   Yee, Marla ^a   Zhu, Zhiqiang ^a   Zhang, Hongtao ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FC RECEPTOR; GRABABODY PROTEIN; PROTEIN A; RECOMBINANT PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY Z DOMAIN FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ANTIGEN FUNCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL ACTIVITY; CELL FUNCTION; CELL SURFACE; CELLULAR DISTRIBUTION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; EFFECTOR CELL; GLYCOSYLATION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TUMOR CELL;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIBODY AFFINITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; CELL LINE; COMPLEMENT ACTIVATION; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULIN G; MICE; NEOPLASMS; PROTEIN BINDING; RECEPTOR, ERBB-2; RECEPTORS, IGG; SINGLE-CHAIN ANTIBODIES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84876422377     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3920     Document Type: Article

References (44)

1. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012;12:278-87.
2. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 2003;325: 979-89.
3. Muthing J, Kemminer SE, Conradt HS, Sagi D, Nimtz M, Karst U, et al. Effects of buffering conditions and culture pH on production rates and glycosylation of clinical phase I anti-melanoma mouse IgG3 monoclonal antibody R24. Biotechnol Bioeng 2003;83:321-34.
4. Suzuki E, Niwa R, Saji S, Muta M, Hirose M, Iida S, et al. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. Clin Cancer Res 2007;13: 1875-82.
5. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009;8:226-34.
6. Anthony RM, Nimmerjahn F. The role of differential IgG glycosylation in the interaction of antibodies with FcgammaRs in vivo. Curr Opin Organ Transplant. 2011;16:7-14.
7. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3- galactose. N Engl J Med 2008;358:1109-17.
8. Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A, Greene MI. The neu-oncogene: Signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 1994;9:2109-23.
9. Pinkas-Kramarski R, Alroy I, Yarden Y. ErbB receptors and EGF-like ligands: Cell lineage determination and oncogenesis through combinatorial signaling. J Mammary Gland Biol Neoplasia 1997;2:97-107.
10. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996;16:5276-87.
11. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, et al. The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984;312:513-6.
12. Drebin JA, Stern DF, Link VC, Weinberg RA, Greene MI. Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature 1984;312:545-8.
13. Drebin JA, Link VC, Weinberg RA, Greene MI. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci U S A 1986;83:9129-33.
14. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993;37:255-63.
15. Zhang H,WangQ, Montone KT, Peavey JE, Drebin JA, Greene MI, et al. Shared antigenic epitopes and pathobiological functions of anti-p185 (her2/neu) monoclonal antibodies. Exp Mol Pathol 1999;67:15-25.
16. Park BW, Zhang HT,WuC, Berezov A, Zhang X, Dua R, et al. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat Biotechnol 2000;18:194-8.
17. Masuda K, Richter M, Song X, Berezov A, Murali R, Greene MI, et al. AHNP-streptavidin: A tetrameric bacterially produced antibody surrogate fusion protein against p185her2/neu. Oncogene 2006;25:7740-6.
18. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987;237:178-82.
19. Worn A, Pluckthun A. An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly. FEBS Lett 1998;427:357-61.
20. Zhang G, Zhang H,WangQ, Lal P, Carroll AM, de la Llera-Moya M, et al. Suppression of human prostate tumor growth by a unique prostatespecific monoclonal antibody F77 targeting a glycolipid marker. Proc Natl Acad Sci U S A 2010;107:732-7.
21. Nilsson B, Moks T, Jansson B, Abrahmsen L, Elmblad A, Holmgren E, et al. A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng 1987;1:107-13.
22. Braisted AC, Wells JA. Minimizing a binding domain from protein A. Proc Natl Acad Sci U S A 1996;93:5688-92.
23. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9-and 2.8-A resolution. Biochemistry 1981;20:2361-70.
24. Cedergren L, Andersson R, Jansson B, Uhlen M, Nilsson B. Mutational analysis of the interaction between staphylococcal protein A and human IgG1. Protein Eng 1993;6:441-8.
25. Radaev S, Motyka S, Fridman WH, Sautes-Fridman C, Sun PD. The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem 2001;276:16469-77.
26. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, DenneyDWJr, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756-60.
27. RodenMM, Lee KH, Panelli MC, Marincola FM. A novel cytolysis assay using fluorescent labeling and quantitative fluorescent scanning technology. J Immunol Methods 1999;226:29-41.
28. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009;27:1122-9.
29. Schlaeth M, Berger S, Derer S, Klausz K, Lohse S, Dechant M, et al. Fcengineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells. Cancer Sci 2010;101:1080-8.
30. McCall AM, Shahied L, Amoroso AR, Horak EM, Simmons HH, Nielson U, et al. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol 2001;166: 6112-7.
31. Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem 2004;279:53907-14.
32. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: Epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997;10:505-20.
33. Kuehnert MJ, Kruszon-Moran D, Hill HA, McQuillan G, McAllister SK, Fosheim G, et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis 2006;193:172-9.
34. Hillson JL, Karr NS, Oppliger IR, Mannik M, Sasso EH. The structural basis of germline-encoded VH3 immunoglobulin binding to staphylococcal protein A. J Exp Med 1993;178:331-6.
35. Kristiansen SV, Pascual V, Lipsky PE. Staphylococcal protein A induces biased production of Ig by VH3-expressing B lymphocytes. J Immunol 1994;153:2974-82.
36. Kozlowski LM, Kunning SR, Zheng Y, Wheatley LM, Levinson AI. Staphylococcus aureus Cowan I-induced human immunoglobulin responses: Preferential IgM rheumatoid factor production and VH3 mRNA expression by protein A-binding B cells. J Clin Immunol 1995;15:145-51.
37. Graille M, Stura EA, Corper AL, Sutton BJ, Taussig MJ, Charbonnier JB, et al. Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: Structural basis for recognition of B-cell receptors and superantigen activity. Proc Natl Acad Sci U S A 2000;97:5399-404.
38. Jansson B, Uhlen M, Nygren PA. All individual domains of staphylococcal protein A show Fab binding. FEMS Immunol Med Microbiol 1998;20:69-78.
39. Gomez MI, O'Seaghdha M, Magargee M, Foster TJ, Prince AS. Staphylococcus aureus protein A activates TNFR1 signaling through conserved IgG binding domains. J Biol Chem 2006;281:20190-6.
40. Gomez MI, Seaghdha MO, Prince AS. Staphylococcus aureus protein A activates TACE through EGFR-dependent signaling. EMBO J 2007;26:701-9.
41. Cai Z, Zhang G, Zhou Z, Bembas K, Drebin JA, Greene MI, et al. Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes. Oncogene 2008;27:3870-4.
42. Hutt M, Farber-Schwarz A, Unverdorben F, Richter F, Kontermann RE. Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains. J Biol Chem 2012;287:4462-9.
43. Cantor JR, Yoo TH, Dixit A, Iverson BL, Forsthuber TG, Georgiou G. Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. Proc Natl Acad SciUS A 2011;108:1272-7.
44. Starovasnik MA, Braisted AC, Wells JA. Structural mimicry of a native protein by a minimized binding domain. Proc Natl Acad Sci U S A 1997;94:10080-5.